Literature DB >> 10954683

Detection and prevention of NSAID-induced enteropathy.

N M Davies1, J Y Saleh, N M Skjodt.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) may cause damage distal to the duodenum. We reviewed the prevalence, clinical spectrum, assessment, pathogenesis, and treatment of adverse effects of NSAIDs on the small intestine. NSAIDs can cause small intestinal perforation, ulcers, and strictures requiring surgery. NSAIDs produce inflammation of the small intestine in 40 to 70% in long-term users, and the associated complications of blood loss and protein loss are difficult management problems. The pathogenesis of NSAID enteropathy is a multi-stage process involving specific biochemical and subcellular organelle damage followed by inflammatory tissue reaction. Various suggested treatments of NSAID-induced enteropathy (e.g., sulphasalazine, misoprostol, and metronidazole) have yet to undergo rigorous clinical trials. Cyclo-oxygenase-2 inhibitors appear to be safer to the small intestine than traditional NSAIDs. Pre-clinical and clinical data suggests meloxicam, celecoxib, nimesulide and rofecoxib may have less small intestine toxicity than traditional non-selective NSAIDs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954683

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  39 in total

1.  Nonsteroidal anti-inflammatory induced small bowel obstruction.

Authors:  R G Casey; M Tan; J Ryan; P Gillen
Journal:  Ir J Med Sci       Date:  2002 Apr-Jun       Impact factor: 1.568

2.  Multiple enterocolic perforations and their possible association with prolonged intake of nimesulide: report of two cases.

Authors:  Corrado Rosario Asteria; Giacomo Batignani; Alessandro Garcea; Francesco Tonelli
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

3.  Carrier-linked mutual prodrugs of biphenylacetic acid as a promising alternative to bioprecursor fenbufen: design, kinetics, and pharmacological studies.

Authors:  Suneela Dhaneshwar; Manisha Kusurkar; Subhash Bodhankar; Gopal Bihani
Journal:  Inflammopharmacology       Date:  2013-11-01       Impact factor: 4.473

4.  Diaphragm disease compared with cryptogenic multifocal ulcerous stenosing enteritis.

Authors:  Sook Hee Chung; Yunju Jo; Sang Ryol Ryu; Sang Bong Ahn; Byoung Kwan Son; Seong Hwan Kim; Young Sook Park; Young Ok Hong
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

5.  Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells.

Authors:  Yumiko Nagano; Hirofumi Matsui; Mutsumi Muramatsu; Osamu Shimokawa; Takeshi Shibahara; Akinori Yanaka; Akira Nakahara; Yasushi Matsuzaki; Naomi Tanaka; Yukio Nakamura
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

6.  Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts.

Authors:  L E M Willemsen; M A Koetsier; S J H van Deventer; E A F van Tol
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 7.  Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies.

Authors:  Urs A Boelsterli; Matthew R Redinbo; Kyle S Saitta
Journal:  Toxicol Sci       Date:  2012-10-22       Impact factor: 4.849

8.  Protective effects of isolated polyphenolic and alkaloid fractions of Ruta graveolens L. on acute and chronic models of inflammation.

Authors:  M Ratheesh; G L Shyni; G Sindhu; A Helen
Journal:  Inflammation       Date:  2010-02       Impact factor: 4.092

Review 9.  Determining small bowel integrity following drug treatment.

Authors:  Simon Smale; Ingvar Bjarnason
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 10.  Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide.

Authors:  Urs A Boelsterli
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.